Biphasic Effects of Vitamin D and FGF23 on Human Osteoclast Biology

Calcified Tissue International

Volumn 97, Issue 1, 2015, Pages 69-79

  Allard, Lise ^a,b   Demoncheaux, Nathalie ^a   Machuca Gayet, Irma ^a,c   Georgess, Dan ^a   Coury Lucas, Fabienne ^a,c   Jurdic, Pierre ^a   Bacchetta, Justine ^a,c,d  

^a UNIVERSITÉ DE LYON   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d HOSPICES CIVILS DE LYON   (France)

Author keywords

Bone resorption; Differentiation; FGF23; Human; Osteoclast; Vitamin D

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; CALCITRIOL; COLONY STIMULATING FACTOR 1; FIBROBLAST GROWTH FACTOR 23; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; VITAMIN D; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BLOOD DONOR; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; MULTINUCLEAR CELL; NORMAL HUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS; DRUG THERAPY; METABOLISM;

BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; FIBROBLAST GROWTH FACTORS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MONOCYTES; OSTEOCLASTS; VITAMIN D;

EID: 84930536554     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-015-0013-6     Document Type: Article

References (33)

1. Razzaque MS (2009) FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol 296:470–476
2. Yamazaki Y, Tamada T, Kasai N et al (2008) Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509–1518
3. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003–4008
4. Yoshiko Y, Wang H, Minamizaki T et al (2007) Mineralized tissue cells are a principal source of FGF23. Bone 40:1565–1573
5. Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408
6. Bacchetta J, Sea JL, Chun RF et al (2013) Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 28:46–55
7. Gattineni J, Alphonse P, Zhang Q, Mathews N, Bates CM, Baum M (2014) Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am J Physiol 306:351–358
8. Kurosu H, Kuro-O M (2009) The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol 299:72–78
9. Farrow EG, Davis SI, Summers LJ, White KE (2009) Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20:955–960
10. Wang H, Yoshiko Y, Yamamoto R et al (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939–948
11. Sitara D, Kim S, Razzaque MS et al (2008) Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 4:e1000154
12. Wesseling-Perry K, Pereira RC, Wang H et al (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511–517
13. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229–238
14. Cappariello A, Maurizi A, Veeriah V, Teti A (2014) The Great Beauty of the osteoclast. Arch Biochem Biophys 558:70–78
15. Takasu H, Sugita A, Uchiyama Y et al (2006) c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest 116:528–535
16. Sakai S, Takaishi H, Matsuzaki K et al (2009) 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 27:643–652
17. Vincent C, Findlay DM, Welldon KJ et al (2009) Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24:1434–1449
18. Kogawa M, Findlay DM, Anderson PH et al (2010) Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology 151:4613–4625
19. Kogawa M, Anderson PH, Findlay DM, Morris HA, Atkins GJ (2010) The metabolism of 25-(OH)vitamin D3 by osteoclasts and their precursors regulates the differentiation of osteoclasts. J Steroid Biochem Mol Biol 121:277–280
20. Itonaga I, Sabokbar A, Neale SD, Athanasou NA (1999) 1,25-Dihydroxyvitamin D(3) and prostaglandin E(2) act directly on circulating human osteoclast precursors. Biochem Biophys Res Commun 264:590–595
21. Fugier-Vivier I, Servet-Delprat C, Rivailler P, Rissoan MC, Liu YJ, Rabourdin-Combe C (1997) Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. J Exp Med 186:813–823
22. Rivollier A, Mazzorana M, Tebib J et al (2004) Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104:4029–4037
23. Harre U, Georgess D, Bang H et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802
24. Bacchetta J, Salusky IB (2012) Evaluation of hypophosphatemia: lessons from patients with genetic disorders. Am J Kidney Dis 59:152–159
25. Hayashibara T, Hiraga T, Sugita A et al (2007) Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res 22:1743–1751
26. Hollberg K, Marsell R, Norgård M, Larsson T, Jonsson KB, Andersson G (2008) Osteoclast polarization is not required for degradation of bone matrix in rachitic FGF23 transgenic mice. Bone 42:1111–1121
27. Chen IP, Wang L, Jiang X, Aguila HL, Reichenberger EJ (2011) A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD). Hum Mol Genet 20:948–961
28. Wang N, Robaye B, Gossiel F, Boeynaems JM, Gartland A (2014) The P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development. FASEB J 28:2249–2259
29. Hu L, Andersson G, Jonsson KB, Melhus H, Lind T (2013) Adamts1 is highly induced in rachitic bones of FGF23 transgenic mice and participates in degradation of non-mineralized bone matrix collagen. Biochem Biophys Res Commun 430:901–906
30. Gutiérrez OM, Mannstadt M, Isakova T et al (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592
31. Wolf M, Molnar MZ, Amaral AP et al (2011) Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22:956–966
32. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K (2009) Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45:1161–1168
33. Shalhoub V, Shatzen EM, Ward SC et al (2012) FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 122:2543–2553